Drug intelligence / Profile preview

PluriPain

Development stage: Unknown
Lead developer: BioAdaptives
Modality: Small Molecules
Administration: Oral

Overview

PluriPain is a branded oral multi-ingredient natural pain relief supplement marketed by BioAdaptives for pain and inflammation support. It is positioned as a dietary supplement rather than an FDA-approved pharmaceutical and is described by the company as a natural COX-2 inhibitor with anti-inflammatory and antioxidant properties. The formulation contains phycocyanin, methylsulfonylmethane, Boswellia serrata, turmeric, magnesium, hyaluronic acid, zinc, AstraGin, and bromelain, and has been discussed for symptom management in pain-related settings including gadolinium deposition disease based on survey data rather than conventional drug development.

Brand names: PluriPain
Other names: PluriPain

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on PluriPain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PluriPain.

Explore the full profile